Figure 3.
Melanocortin receptor pharmacologically of the control NDP-MSH peptide and analogues 6–11 that were modified at the DPhe position. Agonist profiles at the mMC1R and mMC3-5Rs are shown in the top four panels. The mMC3R antagonist profiles for molecules 9 and 11 are shown in the bottom two panels. Both ligands 9 and 11 also possess partial mMC3R agonist activity at the higher concentrations examined.